27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
In a large community-based sample of middle-aged adults, BI predicted an increased risk of stroke and dementia independent of vascular risk factors. 5 key findings →
Participants: 1,694 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease is hypothesized to be caused by an imbalance between β-amyloid (Aβ) production and clearance that leads to Aβ accumulation in the central nervous system (CNS).
Full summary, score breakdown and related studies → Original source Free full text
Furthermore, neuroimaging analysis identified 2 additional loci of high interest for further study. 1 key finding →
Design: case-control study Participants: 168 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This preliminary report suggests that CETP V405 valine homozygosity is associated with slower memory decline and lower incident dementia and AD risk. 5 key findings →
Design: cohort study Participants: 523 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Sensitivity to psychotropic medications presents a therapeutic challenge when treating neuropsychiatric symptoms in patients with dementia with Lewy bodies (DLB). 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer's disease is the most common cause of dementia in elderly people. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Longitudinal changes in motor function may be useful in the early detection of dementia during preclinical stages, when the utility of disease-modifying therapies would be greatest. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Study objective Delirium's adverse effect on long-term mortality in older hospitalized patients is well documented, whereas its effect in older emergency department (ED) patients remains unclear. 4 key findings →
Design: cohort study Participants: 628 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Limiting the clinical use of definite anticholinergics may reduce the incidence of cognitive impairment among African Americans. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These data demonstrate that YKL-40, a putative indicator of neuroinflammation, is elevated in AD and, together with Aβ42, has potential prognostic utility as a biomarker for preclinical AD. 3 key findings →
Participants: 47 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Dramatic increases in the numbers of "oldest old" (aged 85 years and older) across all racial and ethnic groups will also significantly affect the numbers of people living with AD. 1 key finding →
Participants: 200,000 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Dementia, depression and anxiety disorders are the most common psychiatric disorders among older adults in LTC. 3 key findings →
Participants: 74 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Having multiple CMBs or concomitant CMBs and retinopathy is associated with a profile of vascular cognitive impairment. 5 key findings →
Design: cross-sectional Participants: 3,906 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Hippocampal atrophy, posterior cingulate and frontal glucose hypometabolism, and white-matter tract disruption are well described early macroscopic events in Alzheimer's disease. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
What is known Herbal medicines have been used in the treatment of behavioural and psychological symptoms of dementia but with variable response. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
We propose a new method of measuring atrophy of brain structures by simultaneously segmenting longitudinal magnetic resonance (MR) images. 4 key findings →
Design: longitudinal study Participants: 206 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
When planning liaison services, the setting and demographic features of the population need to be taken into account. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
When prospectively validated at the bedside and used as a continuous measure, the ability of the ADEPT score to identify nursing home residents with advanced dementia at high risk of death within 6 months was modest, albeit better than hospice eligibility guidelines. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The findings indicate for the first time in humans that PTSD is associated with selective volume loss of the CA3/dentate gyrus subfields, consistent with animal studies, implying that chronic stress suppresses neurogenesis and dendritic branching in these structures. 4 key findings →
Design: case-control study Participants: 17 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Identifying high-risk populations is an important component of disease prevention strategies. 2 key findings →
Design: longitudinal study Participants: 100 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Much can still be done in the way of service development and provision, GP training and education, and the eradication of stigma attached to dementia, to improve the early detection and management of dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
These initial data suggest that serum protein-based biomarkers can be combined with clinical information to accurately classify AD. 3 key findings →
Design: case-control study Participants: 197 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In addition to known candidate genes, APOE, TOMM40, and one hypothetical gene LOC100129500 partially overlapping APOE; one novel gene, EPC2, and several other interesting genes were associated with CSF biomarkers that are related to AD. 3 key findings →
Participants: 374 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We compared the predictive value of cerebral perfusion as measured by arterial-spin labeling magnetic resonance imaging (ASL-MRI) with MRI-derived hippocampal volume for determining future cognitive and functional decline and subsequent conversion from mild cognitive impairment to dementia. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Despite evidence of ethnic differences in family caregivers' experiences, the extent to which caregiver interventions are culturally tailored to address these differences is unknown. 1 key finding →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →